<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578185</url>
  </required_header>
  <id_info>
    <org_study_id>Lung cancer Biomarker_2018</org_study_id>
    <nct_id>NCT03578185</nct_id>
  </id_info>
  <brief_title>Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy</brief_title>
  <acronym>LC_Biomarker</acronym>
  <official_title>Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Se-Hoon Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to identify the predictive biomarker for immunotherapy using patient
      samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Sample acquisition]

        -  Informed consent is waived for those who agree to donate samples left over from other
           clinical trials or acquired for other purposes to be used for other research by the sign
           to master agreement in advance.

        -  The study will be conducted based on the purposes indicated in the master agreement
           signed by tissue donator [Clinical data acquisition]

        -  Baseline demographics: Sex, Birth date, expire date (last follow-up date for the
           survivals)

        -  Lung cancer treatment history: diagnosed date, treatment history (surgery, radiation
           therapy, chemotherapy, immunotherapy treatment history, and responses), general
           performance, metastatic sites

        -  Lung cancer histologic information: pathology, histologic subtype, EGFR mutation
           profile, ALK-rearrangement result
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>List of biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Neoantigen, tumor mutation burden, MHC compatibility, T-cell receptor and associated immune gene signature (IFN-r, interferons such as IL-2 and interleukin family), T-cell subset (T cell surface marker such as CD4+, CD7+, CD8+, CD16, CD34+, CD38+, CD56+, etc.), PD-1/PD-L1 expression, etc.</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The following analysis will be conducted using samples (tissue, blood, fecal material) form
      the patient who treated with immune checkpoint inhibitor
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Total of 800 lung cancer patients treated with immune checkpoint inhibitor Study will be
        initiated from the date of IRB approval to Dec. 2020 for those who signed for master
        agreement for tissue donation for research purposes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged above or equal to 18

          2. Histologically confirmed lung cancer patients

          3. Patient treated with immune checkpoint inhibitor

        Exculsion Criteria:

        NA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se-hoon Lee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Se-hoon Lee, MD</last_name>
    <phone>+82-10-4759-7640</phone>
    <email>sehoon.lee@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinhee Seo</last_name>
    <phone>+82-70-7014-4158</phone>
    <email>rufina.seo@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se-hoon Lee, MD</last_name>
      <phone>70-7014-4158</phone>
      <phone_ext>82</phone_ext>
      <email>sehoon.lee119@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jinhee Seo, RN</last_name>
      <phone>70-7014-4158</phone>
      <phone_ext>82</phone_ext>
      <email>rufina.seo@samsung.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Joungro-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-min Kim, MD</last_name>
      <phone>2-2072-3559</phone>
      <phone_ext>82</phone_ext>
      <email>gabriel9@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>So-yun Kim, MD</last_name>
      <email>thdus81@hanmail.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dae-ho Lee, MD</last_name>
      <phone>2-3010-5925</phone>
      <phone_ext>82</phone_ext>
      <email>leedaeho@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Da-yi Joung</last_name>
      <phone>2-3010-5925</phone>
      <phone_ext>2</phone_ext>
      <email>joungdayi@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011 Dec 20;29(36):4828-36. doi: 10.1200/JCO.2011.38.0899. Epub 2011 Oct 31. Review.</citation>
    <PMID>22042955</PMID>
  </reference>
  <reference>
    <citation>Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.</citation>
    <PMID>22658128</PMID>
  </reference>
  <reference>
    <citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. Review.</citation>
    <PMID>22437870</PMID>
  </reference>
  <reference>
    <citation>Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.</citation>
    <PMID>20516446</PMID>
  </reference>
  <reference>
    <citation>Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.</citation>
    <PMID>25977344</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Se-Hoon Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

